Press "Enter" to skip to content

Posts tagged as “Oncology”

Cognitive impairment, structural and functional brain morphological sequelae of Hodgkin lymphoma treatment. First results of ongoing translational study – Oncology Learning Network

Published 23rd October 2019 by admin
admin 0
Cognitive impairment, structural and functional brain morphological sequelae of Hodgkin lymphoma treatment. First results of ongoing translational study – Oncology Learning Network

Cognitive impairment, structural and functional brain morphological sequelae of Hodgkin lymphoma treatment. First results of ongoing translational study  Oncology Learning Network “lymphoma cancer” – Google News

Global Cancer Vaccine Market is Expected to Witness a Steady Growth by 2025 : Dendreon Corporation, NeoStem Oncology, ImmunoGen, Inovio Pharmaceuticals, Novarti – Market Research Magazine

Published 23rd October 2019 by admin
admin 0
Global Cancer Vaccine Market is Expected to Witness a Steady Growth by 2025 : Dendreon Corporation, NeoStem Oncology, ImmunoGen, Inovio Pharmaceuticals, Novarti – Market Research Magazine

Global Cancer Vaccine Market is Expected to Witness a Steady Growth by 2025 : Dendreon Corporation, NeoStem Oncology, ImmunoGen, Inovio Pharmaceuticals, Novarti  Market Research Magazine “nigeria cancer” – Google News

Treatment duration as a function of clinician‐level patient volume: mechlorethamine treatment for mycosis fungoides cutaneous T‐cell lymphoma (MF‐CTCL) – Oncology Learning Network

Published 23rd October 2019 by admin
admin 0
Treatment duration as a function of clinician‐level patient volume: mechlorethamine treatment for mycosis fungoides cutaneous T‐cell lymphoma (MF‐CTCL) – Oncology Learning Network

Treatment duration as a function of clinician‐level patient volume: mechlorethamine treatment for mycosis fungoides cutaneous T‐cell lymphoma (MF‐CTCL)  Oncology Learning Network “lymphoma cancer” – Google News

EpiVax Oncology Announces Three Abstracts Accepted for Presentation at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2019) – Manchestertimes

Published 23rd October 2019 by admin
admin 0
EpiVax Oncology Announces Three Abstracts Accepted for Presentation at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2019) – Manchestertimes

EpiVax Oncology Announces Three Abstracts Accepted for Presentation at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2019)  Manchestertimes “bladder cancer” – Google News

Safety Profile and Management of Adverse Events Associated With Duvelisib in Patients With Advanced Hematologic Malignancies – Oncology Learning Network

Published 23rd October 2019 by admin
admin 0
Safety Profile and Management of Adverse Events Associated With Duvelisib in Patients With Advanced Hematologic Malignancies – Oncology Learning Network

Safety Profile and Management of Adverse Events Associated With Duvelisib in Patients With Advanced Hematologic Malignancies  Oncology Learning Network “lymphoma cancer” – Google News

Effect of dose modifications on response to duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma in the DUO trial – Oncology Learning Network

Published 23rd October 2019 by admin
admin 0
Effect of dose modifications on response to duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma in the DUO trial – Oncology Learning Network

Effect of dose modifications on response to duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma in the DUO trial  Oncology Learning Network “lymphoma cancer” – Google News

Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Improves Depth of Response in Transplant-eligible Newly Diagnosed Multiple Myeloma: GRIFFIN Primary Analysis – Oncology Learning Network

Published 23rd October 2019 by admin
admin 0
Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Improves Depth of Response in Transplant-eligible Newly Diagnosed Multiple Myeloma: GRIFFIN Primary Analysis – Oncology Learning Network

Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Improves Depth of Response in Transplant-eligible Newly Diagnosed Multiple Myeloma: GRIFFIN Primary Analysis  Oncology Learning Network “lymphoma cancer” – Google News

The PI3K Inhibitor ME-401 ± Rituximab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL), Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) – Oncology Learning Network

Published 23rd October 2019 by admin
admin 0
The PI3K Inhibitor ME-401 ± Rituximab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL), Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) – Oncology Learning Network

The PI3K Inhibitor ME-401 ± Rituximab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL), Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)  Oncology Learning Network “lymphoma cancer” – Google News

ZUMA-12: A Phase 2 Multicenter Study of Axicabtagene Ciloleucel as a First-Line Therapy in Patients With High-Risk Large B Cell Lymphoma – Oncology Learning Network

Published 23rd October 2019 by admin
admin 0
ZUMA-12: A Phase 2 Multicenter Study of Axicabtagene Ciloleucel as a First-Line Therapy in Patients With High-Risk Large B Cell Lymphoma – Oncology Learning Network

ZUMA-12: A Phase 2 Multicenter Study of Axicabtagene Ciloleucel as a First-Line Therapy in Patients With High-Risk Large B Cell Lymphoma  Oncology Learning Network “lymphoma cancer” – Google News

Aggressive multiple extramedullary plasmacytomas in unusual sites, simultaneously diagnosed with plasma cell leukemia, secondary to relapsed multiple myeloma – Oncology Learning Network

Published 22nd October 2019 by admin
admin 0
Aggressive multiple extramedullary plasmacytomas in unusual sites, simultaneously diagnosed with plasma cell leukemia, secondary to relapsed multiple myeloma – Oncology Learning Network

Aggressive multiple extramedullary plasmacytomas in unusual sites, simultaneously diagnosed with plasma cell leukemia, secondary to relapsed multiple myeloma  Oncology Learning Network “lymphoma cancer” – Google News